Main Page Article Search E-Lerts™ Newsletter: Current E-Lerts™ Newsletter Archives E-Lerts™ Newsletter Recipes Archives Defeat Diabetes® E-Lerts™ Newsletter Subscribe Defeat Diabetes ® News by Daniel H. Rasolt Books You Can Use™ Subscribe to Defeat Diabetes Foundation Mailings
About Diabetes Body Care Children Complications Defeat Diabetes Foundation Drugs    » ACE Inhibitor    » Actos    » Alternative Medicine    » Aspirin    » Avandia    » Byetta    » Drugs    » Exenatide    » Glargine    » Glucophage    » Insulin    » Januvia    » Lantus    » Liraglutide    » Metformin    » Recall    » Research    » Rosiglitazone    » Self-Management    » Statins    » Sulfonylureas    » Victoza Elderly E-Lerts™ Governments & Organizations Health & Fitness Insulin MADDCAP™ Mr. Diabetes® Nutrition Obesity Other Diseases Pregnancy Research Risks Self-Management Supplements Type 1 Warning Signs

 

 

 

     

Lipitor Little Help to Diabetics on Dialysis

Posted: Monday, November 15, 2004

 according to results of a large study presented last week in St. Louis at the meeting of the American Society of Nephrology.

 In the trial, investigators treated a total of 1255 type 2 diabetic patients who were on hemodialysis with Lipitor or a matching placebo pill for an average of four years.

," said. Dr. Christoph Wanner from University Clinic in Wuerzburg "The conservative news," he said, is that the reduction in the combination of cardiac death, non-fatal heart attack and stroke with Lipitor was slight compared with the rate in the placebo group. "There was an 8 percent risk reduction with statin therapy, which is not statistically significant."

This was a bit of a surprise, Wanner noted, given recent findings that Lipitor has significant benefits for people with type 2 diabetes who have not developed major kidney disease.

The take-home message from the current trial "is to provide statin treatment to patients with type 2 diabetes during the early stage of disease progression and not when it's too late," Wanner said.

"Type 2 diabetics who have reached terminal renal failure and are maintained on chronic hemodialysis have the highest risk of cardiovascular death among any patient group," Wanner pointed out. "So probably it's too late in the vascular life of the patient to (start) statin treatment."

 In the trial, investigators treated a total of 1255 type 2 diabetic patients who were on hemodialysis with Lipitor or a matching placebo pill for an average of four years.

," said. Dr. Christoph Wanner from University Clinic in Wuerzburg "The conservative news," he said, is that the reduction in the combination of cardiac death, non-fatal heart attack and stroke with Lipitor was slight compared with the rate in the placebo group. "There was an 8 percent risk reduction with statin therapy, which is not statistically significant."

This was a bit of a surprise, Wanner noted, given recent findings that Lipitor has significant benefits for people with type 2 diabetes who have not developed major kidney disease.

The take-home message from the current trial "is to provide statin treatment to patients with type 2 diabetes during the early stage of disease progression and not when it's too late," Wanner said.

"Type 2 diabetics who have reached terminal renal failure and are maintained on chronic hemodialysis have the highest risk of cardiovascular death among any patient group," Wanner pointed out. "So probably it's too late in the vascular life of the patient to (start) statin treatment."

 

 

Source: Diabetes In Control.com.

 

 

 

 

 

 Costa Rica Travel Corp. will donate a portion of the proceeds to and is a sponsor of Defeat Diabetes Foundation.